GRENOBLE, France, March 12, 2026 (GLOBE NEWSWIRE) -- Koelis, SAS (“Koelis” or the “Company”, www.koelis.com), a leader and innovator in MRI-ultrasound fusion guidance for prostate cancer interventions ...
Nearly 300 abstracts on prostate cancer research from around the world will be presented at the European Association of Urology Congress (EAU26), taking place in London from 13–16 March 2026.
Dr. Matthew Galsky spoke with CURE about the KEYNOTE-B15 trial results and their potential impact on muscle-invasive bladder cancer care. At the 2026 ASCO Genitourinary Cancers Symposium, the ...
12h
Safer Minimally Invasive Treatments in High-Risk & Comorbid Patients with Prostate Enlargement (BPH)
Prostate enlargement, which is called Benign Prostatic Hyperplasia (BPH) is a non-cancerous enlargement and is common in ageing men. As the prostate enlarges, it compresses the urethra and interferes ...
Zacks Investment Research on MSN
Reasons to Add AngioDynamics Stock to Your Portfolio for Now
AngioDynamics ANGO has been gaining from its solid prospects with NanoKnife and an increased focus on cancer treatment markets. The optimism, led by a solid first-quarter fiscal 2026 performance, ...
A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...
Clinically known as benign prostatic hyperplasia (BPH), enlarged prostate is a non‑cancerous condition that affects roughly half of men ages 51 to 60, with incidence increasing ...
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) ('Profound” or the 'Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ...
A groundbreaking surgical procedure has demonstrated how robotics and ultra-low-latency networks could reshape the future of healthcare. A prostate cancer patient in Gibraltar successfully underwent ...
PYLARIFY TruVu™ (piflufolastat F 18) injection (also known as 18F-DCFPyL or PyL) is a fluorinated small molecule PSMA-targeted PET imaging agent that enables visualization of lymph nodes, bone and ...
Axogen, Inc. (AXGN) 47th Annual Raymond James Institutional Investor Conference March 3, 2026 3:25 PM ESTCompany ParticipantsMichael Dale - President, ...
Can AI match radiologists in prostate MRI diagnosis? The PARADIGM trial will assess AI detection of clinically significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results